Clinical trials: Decompensated Hepatitis B Cirrhosis
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Hepatitis B Cirrhosis
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis
Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis…
- Trial name
- HBV-DC (NCT07413549)
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Beijing Tuohua Weiye Biotechnology Co., Ltd.
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatitis B Virus, Decompensated Cirrhosis
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.
- Trial name
- NCT00663182
- Testing
- Entecavir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Decompensated Cirrhosis, Bleeding Varices
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced…
- Trial name
- NCT01370161
- Testing
- TIPS treatment, Medical treatment
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Air Force Military Medical University, China
Decompensated Hepatitis B Cirrhosis
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1.
- Trial name
- FZHYRORDFDHBLC (NCT07017426)
- Testing
- Fuzheng Huayu tablets
- Volunteers
- 432 people
- Sponsor
- Zhiyun Yang
Cirrhosis Due to Hepatitis B
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV…
- Trial name
- NCT02238860
- Testing
- Entacavir, Tenofovir
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Asian Institute Of Medical Sciences
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Liver Cirrhosis
Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with decompensated hepatitis B cirrhosis, and to further explore the…
- Trial name
- NCT05948982
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 18 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Hepatitis B
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem…
- Trial name
- NCT03826433
- Testing
- Peripheral iv
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Hepatitis B, Hepatitis C
A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
Cirrhosis is a diffuse lesion characterized by architectural distortion of the liver because of collagen deposition and development of nodules of regenerating hepatocytes.
- Conditions
- Hepatitis B, Hepatitis C, Liver Cirrhosis
- Trial name
- NCT00562783
- Testing
- Vitaliver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hospital Authority, Hong Kong
Liver Cirrhosis
Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.
- Trial name
- NCT05106972
- Testing
- UC-MSC infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
Hepatitis B
Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver
This is a prospective, randomized, open-label clinical trial designed to compare the antiviral efficacy and safety of entecavir 0.5 mg once daily versus entecavir 1.0 mg once daily in adult patients with hepatitis B virus…
- Trial name
- NCT07816094
- Testing
- Entecavir
- Where
- Bangladesh
- Volunteers
- 48 people
- Sponsor
- Bangladesh Medical University
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Hepatitis, Hepatitis B, Chronic
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Conditions
- Hepatitis, Hepatitis B, Chronic, Cirrhosis
- Trial name
- NCT00076336
- Testing
- Telbivudine, Lamivudine
- Where
- 28 sites in United States, Australia and 19 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Cirrhosis
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection.
- Trial name
- NCT00275652
- Testing
- LdT (Telbivudine) and lamivudine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University